Subscribe

The American College of Rheumatology has updated its position on the use of biosimilars and now advises healthcare providers and clinicians to “incorporate biosimilars, where appropriate, into regimens to treat patients with rheumatologic diseases.”

Washington, DC—On March 7, 2018, FDA Commissioner Scott Gottlieb, MD, delivered a speech to attendees of the America’s Health Insurance Plans National Health Policy Conference that called out pharmacy benefit managers (PBMs) for their role in disincentivizing biosimilar development.

The results of a systematic review support the interchangeability of biosimilar tumor necrosis factorα (TNF)-α inhibitors with their respective reference biologics in treating rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
The first biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin.
London, United Kingdom—Monitoring antidrug antibody formation in those receiving biologic disease-modifying antirheumatic drugs can inform treatment decisions in patients with rheumatic diseases. In particular, patients who developed antibodies to infliximab (Remicade) cross-reacted with the infliximab biosimilar CT-P13—marketed as Remsima or Inflectra—according to data from a multicenter, controlled study of patients with rheumatoid arthritis (RA) and spondylo­arthritis (SpA) presented at the 2016 European League Against Rheumatism Annual Congress.

Results 1 - 5 of 5
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology